Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

101P - Clinicopathological features and behavior of ground glass opacity lung cancer associated with cystic airspace

Date

03 Apr 2022

Session

Poster Display session

Topics

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Ziwen Yu

Citation

Annals of Oncology (2022) 33 (suppl_2): S71-S78. 10.1016/annonc/annonc857

Authors

Z. Yu1, J. Li1, C. Li2, L. Liu1, W. Liang1, J. He3

Author affiliations

  • 1 State Key Laboratory of Respiratory Diseases - The First Affiliated Hospital Of Guangzhou Medical University, Guangzhou/CN
  • 2 State Key Laboratory of Respiratory Diseases - The First Affiliated Hospital Of Guangzhou Medical University, 510000 - Guangzhou/CN
  • 3 The First Affiliated Hospital of Guangzhou Medical University, Guangzhou/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 101P

Background

The aim of our research was to investigate clinicopathological features and degree of malignancy of ground-glass opacity lung cancer associated with cystic airspace (GGO-LCCA), compared with ground-glass opacity lung cancer without cystic airspace (GGO-nLCCA).

Methods

156 patients with GGO-LCCAs were reviewed, focusing on clinical features, histological invasiveness, mutant-gene distribution, and morphological modification on computed tomographic (CT) images. As a control group, 770 patients with GGO-nLCCAs were included. Mutations were examined by targeted next-generation sequencing (NGS). Statistical analysis consisted of Chi-square and Mann-Whitney test.

Results

In the group with GGO-LCCAs, male patients, patients with smoking history, patients with chronic lung disease, patients with pulmonary bullae, and patients with family history of cancer were 75.0% (117/156), 42.3% (66/156), 26.3% (41/156), 34.6% (54/156) and 10.9% (17/156). GGO-LCCAs with lobulated margin, with spiculated margin, with pleural retraction, and with vascular penetration were 12.8% (20/156), 12.8% (20/156), 22.4% (35/156), and 28.2% (44/156). In the analysis of pathology, more lesions of GGO-LCCA were diagnosed as invasive adenocarcinoma (IAC) than GGO-nLCCA (78.8% vs 39.2%, P<0.001). What’s more, micropapillary were observed more frequently in IAC of GGO-LCCAs rather than GGO-nLCCAs (20.7% vs 6.5%, P=0.070). Besides, KRAS (7/49, 14.3% vs 0, P=0.057) mutated more frequently in GGO-LCCAs than in GGO-nLCCAs. Among patients followed up by CT scans, more lesions of GGO-LCCA grew than GGO-nLCCAs (36.7% vs 11.8%, P<0.001). And the group of GGO-LCCA had a shorter median time between baseline and GGO growth, compared with GGO-nLCCA (16.0 months vs 67.0 months, P<0.001).

Conclusions

Patients with GGO-LCCAs had distinct clinical and radiological features. KRAS mutation was more common in GGO-LCCAs. Pathological examination and follow-up CT scans consistently show that GGO-LCCAs are associated with higher aggressiveness.

Legal entity responsible for the study

the First Affiliated Hospital of Guangzhou Medical University.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.